Mediwound Ltd

NASDAQ:MDWDUnited States

Today

Show headlines and story abstract

• *DJ MediWound 3Q Loss/Shr 98c >MDWD, from 24 minutes ago by Dow Jones

  24 minutes ago by Dow Jones
  Companies Mentioned: MDWD

• MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update, from 24 minutes ago by Dow Jones

  24 minutes ago by Dow Jones
  Companies Mentioned: MDWD
  September 30, September 30, 31, -------------------- --------------------- ---------- 2024 2023 2024 2023 2023 Total Revenues 14,382 13,348 4,355 4,776 18,686 Cost of revenues 12,651 10,489 3,678 3,880 15,108 --------- --------- ---------- --------- ---------- Gross profit 1,731 2,859 677 896 3,578 Research and development 5,892 5,659 2,524 1,533 7,467 Selling and Marketing 3,466 3,635 1,063 1,197 4,844 General and administrative 5,672 5,185 2,171 1,415 6,768 Other Income - (224) - (224) (211) --------- --------- ---------- --------- ---------- Total operating expenses 15,030 14,255 5,758 3,921 18,868 --------- --------- ---------- --------- ---------- Operating loss (13,299) (11,396) (5,081) (3,025) (15,290) --------- --------- ---------- --------- ---------- Financial income (expenses), net (12,974) 6,488 (5,180) 877 8,759 ---------- --------- ---------- Taxes on income (43) (65) (21) (48) (185) --------- --------- ---------- --------- ---------- Net loss (26,316) (4,973) (10,282) (2,196) (6,716) ========= ========= ========== ========= ========== Foreign currency translation adjustments 3 (2) (7) 7 (13) ---------- --------- ---------- Total comprehensive loss (26,313) (4,975) (10,289) (2,189) (6,729) ========= ========= ========== ========= ========== Basic and diluted loss per share: ----------------- Net loss per share (2.72) (0.56) (0.98) (0.24) (0.75) Weighted average number of ordinary shares 9,679,599 8,943,205 10,511,288 9,217,390 9,013,144 --------- --------- ---------- --------- ---------- MediWound, Ltd. Unaudited Condensed Consolidated Statements of Cash Flows U.S. dollars in thousands Nine months ended Three months ended Year Ended December September 30, September 30, 31, ------------------ ------------------- 2024 2023 2024 2023 2023 ---------- Cash Flows from Operating Activities: -------------- Net loss (26,316) (4,973) (10,282) (2,196) (6,716) Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to profit and loss items: Depreciation and amortization 1,086 957 361 339 1,303 Share-based compensation 2,316 1,642 1,046 311 1,940 Revaluation of warrants accounted at fair value 12,668 (6,705) 4,661 (782) (8,310) Revaluation of liabilities in respect of IIA grants 711 709 241 217 427 Revaluation of liabilities in respect of TEVA 770 357 564 116 468 Financing income (expenses) and exchange differences of lease liability 238 (206) 221 (184) 257 Increase (decrease) in severance liability, net (46) 80 (94) 13 83 Other income - (224) - (224) (211) Financial income, net (1,486) (1,395) (568) (390) (2,231) Un-realized foreign currency (gain) loss 74 534 (4) 68 189 -------- -------- -------- -------- ---------- 16,331 (4,251) 6,428 (516) (6,085) Changes in asset and liability items: Decrease (increase) in trade receivables 285 6,186 (468) 71 5,658 Decrease (increase) in inventories (161) (1,688) 184 (526) (906) Decrease (increase) in other receivables (283) (198) 291 (320) (894) Decrease in trade payables and accrued expenses (1,948) (1,687) (48) (51) (594) Increase (decrease) in other payables 105 (1,239) 139 287 (928) -------- -------- -------- ---------- (2,002) 1,374 98 (539 ) 2,336 -------- -------- -------- -------- ---------- Net cash used in operating activities (11,987) (7,850 ) (3,756) (3,251 ) (10,465) ======== ======== ======== ======== ========== Unaudited Condensed Consolidated Statements of Cash Flows U.S. dollars in thousands Nine months ended Three months ended Year Ended September 30, September 30, December 31, ------------------- -------------------- 2024 2023 2024 2023 2023 ------------ Cash Flows from Investment Activities: ------------- Purchase of property and equipment (5,467) (4,255) (1,192) (1,685) (6,464) Interest received 1,588 1,225 461 346 1,947 Investment in short term bank deposits, net (9,346) (36,319) (13,555) (4,489) (29,804) --------- -------- ---------- -------- ------------ Net cash used in investing activities (13,225) (39,349) (14,286) (5,828) (34,321) ========= ======== ========== ======== ============ Cash Flows from Financing Activities: ------------- Repayment of lease liabilities (686) (574) (228) (240) (778) Proceeds from exercise of warrants 1,210 - 600 - - Proceeds from issuance of shares and warrants, net 22,436 24,909 22,436 - 24,909 Repayments of IIA grants, net (219) (380) (99) (70) (380) Repayment of liabilities in respect of TEVA (2,834) (834) (2,000) (417) (834) --------- -------- ---------- -------- ------------ Net cash provided by (used in) financing activities 19,907 23,121 20,709 (727) 22,917 ========= ======== ========== ======== ============ Exchange rate differences on cash and cash equivalent balances (86) (538) 18 (81) (160) ========= ======== ========== ======== ============ Increase (decrease) in cash and cash equivalents (5,391) (24,616) 2,685 (9,887) (22,029) Balance of cash and cash equivalents at the beginning of the period 11,866 33,895 3,790 19,166 33,895 -------- ---------- -------- ------------ Balance of cash and cash equivalents at the end of the period 6,475 9,279 6,475 9,279 11,866 ========= ======== ========== ======== ============ MediWound Ltd. Adjusted EBITDA U.S. dollars in thousands Nine months ended Three months ended Year Ended September 30, September 30, December 31, ------------------- -------------------- ------------ 2024 2023 2024 2023 2023 Net loss (26,316) (4,973) (10,282) (2,196) (6,716) Adjustments: Financial income (expenses), net (12,974) 6,488 (5,180) 877 8,759 Other Income, net - 224 - 224 211 Taxes on income (43) (65) (21) (48) (185) Depreciation and amortization (1,086) (957) (361) (339) (1,303) Share-based compensation expenses (2,316) (1,642) (1,046) (311) (1,940) ---------- ------- ---------- -------- ------------ Total adjustments (16,419) 4,048 (6,608) 403 5,542 ---------- ------- ---------- -------- ------------ Adjusted EBITDA (9,897) (9,021) (3,674) (2,599) (12,258) ========== ======= ========== ======== ============